NDA 218276 · Novartis
Fabhalta
Iptacopan Hydrochloride · Oral
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Dec 5, 2023: To treat paroxysmal nocturnal hemoglobinuria
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Dec 5, 2023
Approved uses
4
Original approval plus efficacy supplements
Registered trials
25
15 Phase 3, 11 recruiting
FAERS reports
800
392 serious, 46 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA FABHALTA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b [see Warnings and Precautions (5.1)] . Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for encapsulated bacteria at least 2 weeks prior to the first dose of FABHALTA, unless the risks of delaying therapy with FABHALTA outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated...
What it is approved for
From the label in effect Jul 16, 2026.
FABHALTA is a complement factor B inhibitor, indicated for: the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. ( 1.2 ) the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria. ( 1.3 ) 1.1 Paroxysmal Nocturnal Hemoglobinuria FABHALTA is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). 1.2 Immunoglobulin A Nephropathy FABHALTA is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. 1.3 Complement 3 Glomerulopathy FABHALTA is indicated for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.
Mechanism: Iptacopan binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, generation of downstream effectors, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative pathway of the complement cascade to control both C3b-mediated EVH and terminal complement-mediated IVH. In IgAN, the deposition of galactose deficient IgA1 (Gd-IgA1) containing immune complexes in...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 16, 2026 Supplement 7 · Efficacy · priority review LetterLabelMedication Guide
- Mar 20, 2025 Supplement 4 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Aug 7, 2024 Supplement 1 · Efficacy · priority review LabelLetter
- Dec 5, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- FABHALTA · IPTACOPAN HYDROCHLORIDE EQ 200MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Iptacopan" as an intervention, any sponsor and status, largest first.
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04557462 · 540 participants (planned) · Start Sep 20, 2021 · Primary completion Dec 4, 2030
Drug: LNP023 · For: Primary IgA Nephropathy
Sites: Glendale, Arizona; San Diego, California; San Dimas, California · 161 sites in all
- Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04578834 · 517 participants · Start Jan 25, 2021 · Primary completion Sep 19, 2025
Drug: Placebo; LNP023 · For: IgA Nephropathy
Sites: Glendale, Arizona; Phoenix, Arizona; Los Angeles, California · 177 sites in all
- Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGNPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03955445 · 225 participants (planned) · Start Oct 3, 2019 · Primary completion May 30, 2036
Drug: LNP023 · For: C3 Glomerulopathy; Immune-complex-membranoproliferative Glomerulonephritis
Sites: Aurora, Colorado; Lawrenceville, Georgia; Iowa City, Iowa · 53 sites in all
- Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal HemoglobinuriaPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04747613 · 208 participants · Start Jul 27, 2021 · Primary completion Oct 18, 2027
Drug: Iptacopan · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Duarte, California; Los Angeles, California; Orange, California · 60 sites in all
- A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT05230537 · 168 participants · Start Feb 17, 2022 · Primary completion Aug 19, 2026
Drug: Iptacopan (LNP023); Placebo · For: Age-Related Macular Degeneration
Sites: Fullerton, California; Huntington Beach, California; Rancho Cordova, California · 28 sites in all
- A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06517758 · 146 participants (planned) · Start Jul 31, 2024 · Primary completion Apr 30, 2027
Drug: Iptacopan · For: Generalized Myasthenia Gravis
Sites: Scottsdale, Arizona; Fullerton, California; Sacramento, California · 116 sites in all
- Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGNPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05755386 · 106 participants (planned) · Start Oct 2, 2023 · Primary completion Oct 27, 2028
Drug: Placebo; iptacopan · For: IC-MPGN
Sites: Los Angeles, California; Orange, California; San Francisco, California · 131 sites in all
- Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04817618 · 98 participants (planned) · Start Jul 28, 2021 · Primary completion Jan 29, 2027
Drug: Placebo; iptacopan · For: C3G
Sites: Aurora, Colorado; Miami, Florida; Lawrenceville, Georgia · 88 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache89
- fatigue62
- haemoglobin decreased56
- pyrexia56
- nausea49
- diarrhoea44
- drug ineffective44
- product dose omission issue39
- breakthrough haemolysis37
- off label use35
- pneumonia34
- rash32
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2023 | 6 |
| 2024 | 259 |
| 2025 | 327 |
| 2026 | 207 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fabhalta (Iptacopan HCl)
2024 spending
$32.5M
Beneficiaries
129
724 claims
Per beneficiary
$252,095
$749.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $32,520,195 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.
Perkovic V, Barratt J, Rovin B, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Iptacopan in IgA Nephropathy - Final 24-Month Data.
Barratt J, Eren N, Kashihara N, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Zhang H, Rizk DV, Perkovic V, et al. · Kidney Int 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study.
Kavanagh D, Bomback AS, Vivarelli M, et al. · Lancet 2025 · Randomized Controlled Trial, Multicenter Study
- Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.
Risitano AM, Kulasekararaj AG, Scheinberg P, et al. · Lancet Haematol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.
Dixon BP, Bomback AS, Rich C, et al. · Adv Ther 2026 · Clinical Trial, Phase III, Comparative Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.